Omada Health CEO Duffy's Stock Sale Raises Concerns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: NASDAQ.COM
- Insider Selling: Omada Health's CEO Sean P. Duffy sold 17,258 shares from June 24 to June 26 for $342,000, representing about 1.4% of his direct holdings, raising concerns about the company's outlook among investors.
- Trading Plan Context: The sale was executed under a 10b5-1 trading plan adopted on March 13, 2026, which, while typically seen as compliant, still raises questions about executive confidence, especially so soon after the IPO.
- Market Reaction and Forecast: Although Duffy's sale may be viewed as a personal financial decision, analysts note that Omada is expected to see a 25% sales increase this year, contrasting sharply with the CEO's stock sale, potentially undermining investor confidence in the company's future.
- Investor Caution: With Duffy selling shares while Omada Health is not listed among the top investment picks by The Motley Fool Stock Advisor, this could heighten investor caution regarding the stock, particularly in light of the insider selling.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OMDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OMDA
Wall Street analysts forecast OMDA stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 22.850
Low
17.00
Averages
27.00
High
32.00
Current: 22.850
Low
17.00
Averages
27.00
High
32.00
About OMDA
Omada Health Inc. is a virtual-first healthcare provider that nurtures lifelong health. The Company has one operating segment, namely all virtual care program product offerings. The Company’s member-facing platform is designed to offer an integrated experience that encompasses the full range of direct interactions. It offers range of programs like Omada for Prevention & Weight Health, Omada for Diabetes, Omada for Hypertension, Omada for musculoskeletal (MSK), and Omada GLP-1 Care Tracks. Its Omada for Prevention & Weight Health programs focus on prediabetes and weight management, two critical elements of preventing diabetes and heart disease. Its Omada for Diabetes program is designed to help members with type 1 or type 2 diabetes achieve stable blood glucose levels and meet and reach their goals for reducing hemoglobin A1C. Its Omada for Hypertension is designed to help reduce members blood pressure and help them maintain healthy blood pressure.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Omada Health CEO's Share Sale Raises Concerns
- Insider Selling Activity: Omada Health CEO Sean P. Duffy sold 17,258 shares between June 24 and June 26, 2026, for approximately $342,000, marking the largest single sell transaction by Duffy in the past year, indicating available capacity following prior planned sales.
- Ownership Percentage Change: Post-transaction, Duffy's direct ownership decreased from 0.6928% to 0.6638%, leaving him with a total of 1,246,262 shares (394,603 direct and 851,659 indirect), reflecting a slight dilution of his control over the company.
- Market Reaction and Pricing: The shares were sold at a weighted average price of $19.82, while Omada Health closed at $20.89 on June 26, suggesting ongoing market confidence despite the CEO's sale, which may raise investor concerns about leadership commitment.
- Trading Plan Context: This sale was executed under a 10b5-1 trading plan adopted on March 13, 2026, indicating a pre-established liquidity strategy rather than a discretionary action, yet investors should remain cautious of the potential negative signals from insider selling.
See More
Omada Health CEO Duffy's Stock Sale Raises Concerns
- Insider Selling: Omada Health's CEO Sean P. Duffy sold 17,258 shares from June 24 to June 26 for $342,000, representing about 1.4% of his direct holdings, raising concerns about the company's outlook among investors.
- Trading Plan Context: The sale was executed under a 10b5-1 trading plan adopted on March 13, 2026, which, while typically seen as compliant, still raises questions about executive confidence, especially so soon after the IPO.
- Market Reaction and Forecast: Although Duffy's sale may be viewed as a personal financial decision, analysts note that Omada is expected to see a 25% sales increase this year, contrasting sharply with the CEO's stock sale, potentially undermining investor confidence in the company's future.
- Investor Caution: With Duffy selling shares while Omada Health is not listed among the top investment picks by The Motley Fool Stock Advisor, this could heighten investor caution regarding the stock, particularly in light of the insider selling.
See More
Omada Health Reports Milestone Q1 2026 Earnings with Strong Growth
- Significant Revenue Growth: Omada Health reported Q1 2026 revenue of $78 million, a 42% year-over-year increase, surpassing analyst estimates of $74.09 million, indicating strong market performance and growth potential.
- Membership Milestone: The total membership reached 1,025,000 in Q1, reflecting a 51% year-over-year growth, marking a crucial milestone in expanding the customer base and enhancing market competitiveness.
- Improved Profitability: The company achieved an adjusted EBITDA of $1 million in Q1, with GAAP net loss narrowing to $3 million, demonstrating positive progress in cost control and profitability, especially during its historically most cost-intensive quarter.
- Optimistic Outlook: Omada raised its full-year revenue guidance to $322 million to $330 million, with adjusted EBITDA expectations of $14 million to $20 million, reflecting management's confidence in future growth, particularly in promoting GLP-1 prescribing capabilities.
See More
Omada Health Study Shows Significant Weight Loss with GLP-1 Therapy
- Significant Weight Loss: A study by Omada Health reveals that members in the GLP-1 Care Track lost an average of 6.0% of their body weight, 1.8 times more than the 3.3% loss in the control group, highlighting the program's effectiveness in promoting substantial weight loss.
- Body Composition Improvements: Participants in the Omada program reduced their body fat percentage by 3.3%, double that of the control group, while increasing muscle mass by nearly three times, demonstrating the program's success in enhancing body composition.
- Mental Health Benefits: The study also indicated that Omada members reported significant improvements in mental health, physical functioning, and confidence in their weight loss efforts, suggesting that the program addresses overall well-being, not just weight metrics.
- Long-term Clinical Impact: Omada Health's president emphasized that the success of GLP-1 companion programs should focus on high-quality weight loss, which is crucial for long-term health outcomes and the return on investment potential of GLP-1 treatments.
See More
Omada Health to Release Q1 2026 Results on May 7
- Earnings Release Schedule: Omada Health will announce its Q1 2026 results on May 7, 2026, after market close, and will host a conference call at 4:30 PM ET the same day to provide detailed insights into its financial performance and future outlook.
- Conference Call Details: The call will feature a live audio webcast available online, with a replay accessible for approximately 12 months post-call, ensuring that investors who cannot attend live can still access critical information.
- Company Background: Omada Health focuses on innovating healthcare delivery in the U.S., aiming to improve chronic disease management during the intervals between doctor visits by utilizing a virtual-first model that combines human-led care teams, connected devices, and AI technology to provide personalized support to over two million members.
- Market Impact Analysis: Omada Health's approach not only addresses gaps in traditional healthcare systems but also enhances its competitive edge in chronic disease management through innovative services like GLP-1 therapy support, which is expected to attract more partnerships with employers and health plans.
See More
Omada Health Receives Market Outperform Rating from Citizens
- Market Coverage Rating: Citizens initiated coverage on Omada Health (OMDA) with a Market Outperform rating and an $18 price target, highlighting the compelling risk-reward profile of the virtual care provider.
- Customer Relationship Expansion: Analyst Constantine Davides noted that Omada's market reach has surpassed 2,000 customer relationships, showcasing its diversified platform advantages in weight loss and diabetes, thereby enhancing its competitive position.
- Valuation Analysis: Since its IPO in 2025, Omada has traded at an average EV/NTM revenue multiple of 3.5x, while currently trading at 1.7x based on Citizens' 2026 revenue estimates, indicating significant undervaluation potential.
- Optimistic Growth Outlook: Davides projects that OMDA's membership could exceed 1 million in 2025, with revenue and EBITDA CAGR estimates of 16% and 44% over the next four years, suggesting ample runway for sustained double-digit growth in the coming years.
See More
Omada Health CEO's Share Sale Raises Concerns
- Insider Selling Activity: Omada Health CEO Sean P. Duffy sold 17,258 shares between June 24 and June 26, 2026, for approximately $342,000, marking the largest single sell transaction by Duffy in the past year, indicating available capacity following prior planned sales.
- Ownership Percentage Change: Post-transaction, Duffy's direct ownership decreased from 0.6928% to 0.6638%, leaving him with a total of 1,246,262 shares (394,603 direct and 851,659 indirect), reflecting a slight dilution of his control over the company.
- Market Reaction and Pricing: The shares were sold at a weighted average price of $19.82, while Omada Health closed at $20.89 on June 26, suggesting ongoing market confidence despite the CEO's sale, which may raise investor concerns about leadership commitment.
- Trading Plan Context: This sale was executed under a 10b5-1 trading plan adopted on March 13, 2026, indicating a pre-established liquidity strategy rather than a discretionary action, yet investors should remain cautious of the potential negative signals from insider selling.
See More
Omada Health CEO Duffy's Stock Sale Raises Concerns
- Insider Selling: Omada Health's CEO Sean P. Duffy sold 17,258 shares from June 24 to June 26 for $342,000, representing about 1.4% of his direct holdings, raising concerns about the company's outlook among investors.
- Trading Plan Context: The sale was executed under a 10b5-1 trading plan adopted on March 13, 2026, which, while typically seen as compliant, still raises questions about executive confidence, especially so soon after the IPO.
- Market Reaction and Forecast: Although Duffy's sale may be viewed as a personal financial decision, analysts note that Omada is expected to see a 25% sales increase this year, contrasting sharply with the CEO's stock sale, potentially undermining investor confidence in the company's future.
- Investor Caution: With Duffy selling shares while Omada Health is not listed among the top investment picks by The Motley Fool Stock Advisor, this could heighten investor caution regarding the stock, particularly in light of the insider selling.
See More
Omada Health Reports Milestone Q1 2026 Earnings with Strong Growth
- Significant Revenue Growth: Omada Health reported Q1 2026 revenue of $78 million, a 42% year-over-year increase, surpassing analyst estimates of $74.09 million, indicating strong market performance and growth potential.
- Membership Milestone: The total membership reached 1,025,000 in Q1, reflecting a 51% year-over-year growth, marking a crucial milestone in expanding the customer base and enhancing market competitiveness.
- Improved Profitability: The company achieved an adjusted EBITDA of $1 million in Q1, with GAAP net loss narrowing to $3 million, demonstrating positive progress in cost control and profitability, especially during its historically most cost-intensive quarter.
- Optimistic Outlook: Omada raised its full-year revenue guidance to $322 million to $330 million, with adjusted EBITDA expectations of $14 million to $20 million, reflecting management's confidence in future growth, particularly in promoting GLP-1 prescribing capabilities.
See More
Omada Health Study Shows Significant Weight Loss with GLP-1 Therapy
- Significant Weight Loss: A study by Omada Health reveals that members in the GLP-1 Care Track lost an average of 6.0% of their body weight, 1.8 times more than the 3.3% loss in the control group, highlighting the program's effectiveness in promoting substantial weight loss.
- Body Composition Improvements: Participants in the Omada program reduced their body fat percentage by 3.3%, double that of the control group, while increasing muscle mass by nearly three times, demonstrating the program's success in enhancing body composition.
- Mental Health Benefits: The study also indicated that Omada members reported significant improvements in mental health, physical functioning, and confidence in their weight loss efforts, suggesting that the program addresses overall well-being, not just weight metrics.
- Long-term Clinical Impact: Omada Health's president emphasized that the success of GLP-1 companion programs should focus on high-quality weight loss, which is crucial for long-term health outcomes and the return on investment potential of GLP-1 treatments.
See More
Omada Health to Release Q1 2026 Results on May 7
- Earnings Release Schedule: Omada Health will announce its Q1 2026 results on May 7, 2026, after market close, and will host a conference call at 4:30 PM ET the same day to provide detailed insights into its financial performance and future outlook.
- Conference Call Details: The call will feature a live audio webcast available online, with a replay accessible for approximately 12 months post-call, ensuring that investors who cannot attend live can still access critical information.
- Company Background: Omada Health focuses on innovating healthcare delivery in the U.S., aiming to improve chronic disease management during the intervals between doctor visits by utilizing a virtual-first model that combines human-led care teams, connected devices, and AI technology to provide personalized support to over two million members.
- Market Impact Analysis: Omada Health's approach not only addresses gaps in traditional healthcare systems but also enhances its competitive edge in chronic disease management through innovative services like GLP-1 therapy support, which is expected to attract more partnerships with employers and health plans.
See More
Omada Health Receives Market Outperform Rating from Citizens
- Market Coverage Rating: Citizens initiated coverage on Omada Health (OMDA) with a Market Outperform rating and an $18 price target, highlighting the compelling risk-reward profile of the virtual care provider.
- Customer Relationship Expansion: Analyst Constantine Davides noted that Omada's market reach has surpassed 2,000 customer relationships, showcasing its diversified platform advantages in weight loss and diabetes, thereby enhancing its competitive position.
- Valuation Analysis: Since its IPO in 2025, Omada has traded at an average EV/NTM revenue multiple of 3.5x, while currently trading at 1.7x based on Citizens' 2026 revenue estimates, indicating significant undervaluation potential.
- Optimistic Growth Outlook: Davides projects that OMDA's membership could exceed 1 million in 2025, with revenue and EBITDA CAGR estimates of 16% and 44% over the next four years, suggesting ample runway for sustained double-digit growth in the coming years.
See More
